ÂÜÀòÂÒÂ×

Dr. Levy has spent his career in ophthalmology and is a proven leader with a depth of experience in Drug and Device Development, Clinical Development and Medical Affairs. Dr. Levy has successfully led 5 New Drug Applications (NDA’s) in Ophthalmic Pharmaceuticals, all approved and commercialized.

Prior to InflammX, Dr. Levy was Chief Medical Officer at Aerie Pharmaceuticals where he was a member of the Executive team that took the company public through a successful IPO. Prior to that he spent 15 years at Bausch & Lomb as Vice President R&D and then Chief Medical Officer for the Corporation. In these evolutionary roles he was responsible for Global Clinical and Product Development, Global Product Safety and Medical Affairs. Prior to joining Bausch & Lomb, Dr. Levy was Associate Professor in the Department of Ophthalmology at California Pacific Medical Center in San Francisco, completed NEI courses in Epidemiology and Biostatistics in Vision Research and was a clinical investigator for numerous products in development and an advisor and consultant to the ophthalmic industry. Dr. Levy holds an appointment as Clinical Professor in the Department of Ophthalmology at the University of Rochester’s School of Medicine. He is a healthcare advisor to Spindletop Capital and has served on the boards of both public and private companies developing products in Ophthalmology. He received a Doctor of Optometry degree from the University of California at Berkeley and did his post-graduate work in Comparative Anatomy and Physiology of the Eye at the University of Waterloo in Canada, where he received a Master of Science degree.